The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …

Allergic rhinitis (AR) and asthma represent global health problems for all age groups.
Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on …

Rationale: Indacaterol is the first once-daily, long-acting inhaled β 2 -agonist bronchodilator
studied in patients with chronic obstructive pulmonary disease (COPD). Objectives: To …

The Global Initiative for Asthma (GINA) was established in 1993 by the World Health
Organization and the US National Heart Lung and Blood Institute to improve asthma awareness, …

The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease
and depends on many factors. Grading of Recommendations Assessment, Development …

GINA no longer recommends treating adults/adolescents with asthma with short-acting
bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily …

Several unmet needs have been identified in allergic rhinitis: identification of the time of
onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification, …

Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic
COPD and allergic rhinitis are a global health concern. Despite the coexistence of these …

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World
Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic …

Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …